Keyphrases
Type 2 Diabetic Patients
100%
Placebo-controlled Trial
100%
Oxidative Stress
40%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
20%
High Performance Liquid Chromatography-tandem Mass Spectrometry (HPLC-MS/MS)
20%
Adult Male
20%
National Conference
20%
Type 2 Diabetes Mellitus (T2DM)
20%
Treatment Strategy
20%
High Risk
20%
Trial Registration
20%
RNA Oxidation
20%
Intensive Care Medicine
20%
Glycemic Control
20%
Ethics
20%
Ferritin
20%
ICH-GCP
20%
Once-daily
20%
Placebo-controlled Study
20%
Vascular Complications
20%
Oxidative Modification
20%
Macrovascular Disease
20%
Placebo
20%
Urinary Excretion
20%
Registration Trial
20%
Declaration of Helsinki
20%
Cardiovascular Disease
20%
High-performance Liquid Chromatography
20%
Biomedical Ethics
20%
Malondialdehyde
20%
8-oxoguanine
20%
Iron Metabolism
20%
Increased Mortality
20%
8-oxo-7,8-dihydroguanosine
20%
Protection Agency
20%
International Conference
20%
University of Copenhagen
20%
Plasma Parameters
20%
Transferrin
20%
Transferrin Saturation
20%
Cardiovascular Risk
20%
International Journals
20%
Data Protection
20%
Cardiovascular Outcomes
20%
Ethics Approval
20%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Non Insulin Dependent Diabetes Mellitus
100%
Empagliflozin
100%
Nucleic Acid
100%
Transferrin
40%
Iron
40%
Malonaldehyde
20%
8 Hydroxydeoxyguanosine
20%
Placebo-Controlled Study
20%
High Performance Liquid Chromatography
20%
Diseases
20%
Cardiovascular Disease
20%
Ferritin
20%
Sodium Glucose Cotransporter 2 Inhibitor
20%
Ultra High Performance Liquid Chromatography
20%
Medicine and Dentistry
Nucleic Acid Modification
100%
Ultra Performance Liquid Chromatography-Tandem Mass Spectrometry
20%